US FDA Approves Expanded Use of Moderna's RSV Vaccine for At-risk Adults

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at...Reuters Health Information